|
Sign In to gain access to subscriptions and/or personal tools.
|
Overexpression of Cytochrome P-450 Isoforms Involved in Aflatoxin B1 Bioactivation in Human Liver with Cirrhosis and Hepatitis
Gordon M. Kirby
Lady Davis Institute for Medical Research and Departments of Medicine, Oncology and Pathology, Jewish General Hospital and McGill University, Montreal, Canada H3T 1E2
Gerald Batist
Lady Davis Institute for Medical Research and Departments of Medicine, Oncology and Pathology, Jewish General Hospital and McGill University, Montreal, Canada H3T 1E2
Lesley Alpert
Lady Davis Institute for Medical Research and Departments of Medicine, Oncology and Pathology, Jewish General Hospital and McGill University, Montreal, Canada H3T 1E2
Esther Lamoureux
Lady Davis Institute for Medical Research and Departments of Medicine, Oncology and Pathology, Jewish General Hospital and McGill University, Montreal, Canada H3T 1E2
Ross G. Cameron
Department of Pathology, Toronto General Hospital, Toronto, Canada M5G 2C4
Moulay A. Alaoui-Jamali
Lady Davis Institute for Medical Research and Departments of Medicine, Oncology and Pathology, Jewish General Hospital and McGill University, Montreal, Canada H3T 1E2
Studies were carried out to test the hypothesis that inflammatory liver disease increases the expression of specific cytochrome P-450 isoenzymes involved in aflatoxin B1 (AFB) activation. The immunohistochemical expression and localization of various human cytochrome P-450 isoforms, including CYP2A6, CYP1A2, CYP3A4, and CYP2B1, were examined in normal human liver and liver with hepatitis and cirrhosis. The constitutive expression of CYP3A4 in normal liver showed a characteristic pattern of distribution in centrilobular hepatocytes, whereas CYP1A2, CYP2A6, and CYP2B1 1 were expressed uniformly throughout the liver acinus. In sections of liver infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), the expression of CYP2A6 was markedly increased in hepatocytes immediately adjacent to areas of fibrosis and inflammation. CYP3A4 and CYP2B 1 were induced to a lesser degree, and expression of CYP1A2 was unaffected. In HBV-infected liver, double immunostaining revealed that overexpression of CYP2A6 occurred in hepatocytes expressing the HBV core antigen. In HCV-infected liver, CYP2A6, CYP3A4, and CYP2B 1 were overexpressed in hepatocytes with hemosiderin pigmentation. These results suggest that alterations in phenotypic expression of specific P-450 isoenzymes in hepatocytes associated with hepatic inflammation and cirrhosis might increase susceptibility to AFB genotoxicity.
Key Words: Hepatitis B virus (HBV) • hepatitis C virus (HCV) • hepatitis • cytochrome P-450s • genotoxicity
Toxicologic Pathology, Vol. 24, No. 4,
458-467 (1996)
DOI: 10.1177/019262339602400408
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. D. Fisher, A. J. Lickteig, L. M. Augustine, J. Ranger-Moore, J. P. Jackson, S. S. Ferguson, and N. J. Cherrington
Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease
Drug Metab. Dispos.,
October 1, 2009;
37(10):
2087 - 2094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Onica, K. Nichols, M. Larin, L. Ng, A. Maslen, Z. Dvorak, J.-M. Pascussi, M.-J. Vilarem, P. Maurel, and G. M. Kirby
Dexamethasone-Mediated Up-Regulation of Human CYP2A6 Involves the Glucocorticoid Receptor and Increased Binding of Hepatic Nuclear Factor 4{alpha} to the Proximal Promoter
Mol. Pharmacol.,
February 1, 2008;
73(2):
451 - 460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. R. Anderson, A. Hasan, H. Yin, I. Qadri, and L. C. Quattrochi
Regulation of the CYP1A1 Gene by 2,3,7,8-Tetrachlorodibenzo-p-dioxin but Not by beta-Naphthoflavone or 3-Methylcholanthrene Is Altered in Hepatitis C Virus Replicon-Expressing Cells
Mol. Pharmacol.,
September 1, 2006;
70(3):
1062 - 1070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hukkanen, P. Jacob III, and N. L. Benowitz
Metabolism and Disposition Kinetics of Nicotine
Pharmacol. Rev.,
March 1, 2005;
57(1):
79 - 115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Christian, M. Lang, P. Maurel, and F. Raffalli-Mathieu
Interaction of Heterogeneous Nuclear Ribonucleoprotein A1 with Cytochrome P450 2A6 mRNA: Implications for Post-Transcriptional Regulation of the CYP2A6 Gene
Mol. Pharmacol.,
June 1, 2004;
65(6):
1405 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Luyendyk, K. C. Shores, P. E. Ganey, and R. A. Roth
Bacterial Lipopolysaccharide Exposure Alters Aflatoxin B1 Hepatotoxicity: Benchmark Dose Analysis for Markers of Liver Injury
Toxicol. Sci.,
July 1, 2002;
68(1):
220 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nowell, C. Sweeney, G. Hammons, F. F. Kadlubar, and N. P. Lang
CYP2A6 Activity Determined by Caffeine Phenotyping: Association with Colorectal Cancer Risk
Cancer Epidemiol. Biomarkers Prev.,
April 1, 2002;
11(4):
377 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. T. Morgan
Regulation of Cytochrome P450 by Inflammatory Mediators: Why and How?
Drug Metab. Dispos.,
March 1, 2001;
29(3):
207 - 212.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S.E. Chuang, M.L. Kuo, C.H. Hsu, C.R. Chen, J.K. Lin, G.M. Lai, C.Y. Hsieh, and A.L. Cheng
Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis
Carcinogenesis,
February 1, 2000;
21(2):
331 - 335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Kammer, S. H. van der Burg, B. Grabscheid, I. P. Hunziker, K. M.C. Kwappenberg, J. Reichen, C. J.M. Melief, and A. Cerny
Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition
J. Exp. Med.,
July 19, 1999;
190(2):
169 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Jaitovitch-Groisman, N. Fotouhi-Ardakani, R. L. Schecter, A. Woo, M. A. Alaoui-Jamali, and G. Batist
Modulation of Glutathione S-Transferase Alpha by Hepatitis B Virus and the Chemopreventive Drug Oltipraz
J. Biol. Chem.,
October 20, 2000;
275(43):
33395 - 33403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
